Biomedical Science Letters (대한의생명과학회지)

The Korean Society for Biomedical Laboratory Sciences (대한의생명과학회)
권호 표지
DOI QR코드

DOI QR Code

Tumor Induces the Expansion of Foxp3+CD25high and CD11b+Gr-1+ Cell Population in the Early Phase of Tumor Progression

  • Lee, Na Kyung (Department of Biomedical Laboratory Science, Soon Chun Hyang University) ;
  • Kim, Hong Sung (Department of Biomedical Laboratory Science, Korea Nazarene University)
  • Received : 2015.08.07
  • Accepted : 2015.10.26
  • Published : 2015.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

It is well reported that tumor cells can regulate host immune systems. To identify the detailed changes of immune cells between tumor bearing mice and normal mice, we evaluated the systemic immune cell phenotype of B16F10 tumor bearing mice in a time dependent manner. The lymphocytic population (CD4+ and CD8+ T cells) of tumor bearing mice significantly decreased compared to that of normal mice. We found that the Foxp3+CD25+ CD4 T cell decreased, but the Foxp3+$CD25^{high}$ CD4 T cell significantly increased. All subpopulations of CD8 T cells decreased, except the CD62L-CD44+ CD8 T cell subpopulation. The myeloid cell population (CD11b+ and Gr-1+ cells) of tumor bearing mice significantly increased. Specifically, Foxp3+$CD25^{high}$ CD4 T cell and CD11b+Gr-1+ cells significantly increased in early phase of tumor progression. These results are helpful to understand the change of the systemic immune cell subpopulation of tumor bearing mice in a time-dependent manner.

Keywords

References

  1. Bronte V, Apolloni E, Cabrelle A, Ronca R, Serafini P, Zamboni P, Restifo NP, Zanovello P. Identification of a CD11b(+)/Gr-1(+)/D31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood. 2000. 96: 3838-3846.
  2. Chatenoud L. Natural and induced T CD4+CD25+FOXP3+ regulatory T cells. Methods Mol Biol. 2011. 677: 3-13.
  3. Cheng M, Chen Y, Xiao W, Sun R, Tian Z. NK cell-based immunotherapy for malignant diseases. Cell Mol Immunol. 2013. 10: 230-252. https://doi.org/10.1038/cmi.2013.10
  4. den Boer AT, van Mierlo GJ, Fransen MF, Melief CJ, Offringa R, Toes RE. The tumoricidal activity of memory CD8+ T cells is hampered by persistent systemic antigen, but full functional capacity is regained in an antigen-free environment. J Immunol. 2004. 172: 6074-6079. https://doi.org/10.4049/jimmunol.172.10.6074
  5. Fousteri G, Dave A, Juedes A, Juntti T, Morin B, Togher L, Farber DL, von Herrath M. Increased memory conversion of naive CD8 T cells activated during late phases of acute virus infection due to decreased cumulative antigen exposure. PloS One. 2011. 6: e14502. https://doi.org/10.1371/journal.pone.0014502
  6. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009. 9: 162-174. https://doi.org/10.1038/nri2506
  7. Gotthardt D, Putz EM, Straka E, Kudweis P, Biaggio M, Poli V, Strobl B, Muller M, Sexl V. Loss of STAT3 in murine NK cells enhances NK cell-dependent tumor surveillance. Blood. 2014. 124: 2370-2379. https://doi.org/10.1182/blood-2014-03-564450
  8. Hadaschik B, Su Y, Huter E, Ge Y, Hohenfellner M, Beckhove P. Antigen specific T-cell responses against tumor antigens are controlled by regulatory T cells in patients with prostate cancer. J Urol. 2012. 187: 1458-1465. https://doi.org/10.1016/j.juro.2011.11.083
  9. Kilinc MO, Gu T, Harden JL, Virtuoso LP, Egilmez NK. Central role of tumor-associated CD8+ T effector/memory cells in restoring systemic antitumor immunity. J Immunol. 2009. 182: 4217-4225. https://doi.org/10.4049/jimmunol.0802793
  10. Klebanoff CA, Gattinoni L, Torabi-Parizi P, Kerstann K, Cardones AR, Finkelstein SE, Palmer DC, Antony PA, Hwang ST, Rosenberg SA. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci USA. 2005. 102: 9571-9576. https://doi.org/10.1073/pnas.0503726102
  11. Kusmartsev S, Nefedova Y, Yoder D, Gabrilovich DI. Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol. 2004. 172: 989-999. https://doi.org/10.4049/jimmunol.172.2.989
  12. Lambert PH, Liu M, Siegrist CA. Can successful vaccines teach us how to induce efficient protective immune responses? Nat Med. 2005. 11: S54-62. https://doi.org/10.1038/nm1216
  13. Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, Weber JS, Johnson D, Swetter S, Thompson J, Greenberg PD. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med. 1999. 5: 677-685. https://doi.org/10.1038/9525
  14. Li Q, Pan PY, Gu P, Xu D, Chen SH. Role of immature myeloid Gr-1+ cells in the development of antitumor immunity. Cancer Res. 2004. 64: 1130-1139. https://doi.org/10.1158/0008-5472.CAN-03-1715
  15. Movahedi K, Guilliams M, Van den Bossche J, Van den Bergh R, Gysemans C, Beschin A, De Baetselier P, Van Ginderachter JA. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood. 2008. 111: 4233-4244. https://doi.org/10.1182/blood-2007-07-099226
  16. Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer. 2010. 127: 759-767.
  17. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature. 2001. 411: 380-384. https://doi.org/10.1038/35077246
  18. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two sub-sets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999. 401: 708-712. https://doi.org/10.1038/44385
  19. Savage PA, Malchow S, Leventhal DS. Basic principles of tumor-associated regulatory T cell biology. Trends Immunol. 2013. 34: 33-40. https://doi.org/10.1016/j.it.2012.08.005
  20. Speiser DE, Lienard D, Rufer N, Rubio-Godoy V, Rimoldi D, Lejeune F, Krieg AM, Cerottini JC, Romero P. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest. 2005. 115: 739-746. https://doi.org/10.1172/JCI23373
  21. Wesolowski R, Markowitz J, Carson WE, 3rd. Myeloid derived suppressor cells - a new therapeutic target in the treatment of cancer. J Immunother Cancer. 2013. 1: 10. https://doi.org/10.1186/2051-1426-1-10
  22. Youn JI, Nagaraj S, Collazo M, Gabrilovich DI. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol. 181: 5791-5802.
  23. Zou W. 2005. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer. 2008. 5: 263-274.